• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Enterprises Announces CEO Transition Plan

    2/10/21 8:01:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    PROVO, Utah, Feb. 10, 2021 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced Ryan Napierski, the company's president, has been selected by the Nu Skin Board of Directors to become the company's next president and chief executive officer. Napierski will succeed Nu Skin CEO Ritch Wood, who has decided to retire as CEO effective Sept. 1, 2021, after a successful 30-year career with the company. Wood will continue as an executive advisor through early 2022, and it is anticipated that Napierski will assume Wood's position on the Board at the 2021 stockholder meeting in June.

    Wood, who served as Nu Skin's chief financial officer for 14 years before becoming CEO in 2017, has been a key leader at Nu Skin. Under his leadership and vision as CEO, Nu Skin has increased its emphasis on being a customer-focused organization; expanded its product innovation, particularly in beauty devices; and transitioned to a digitally enabled social commerce model. He introduced a greater emphasis on sustainability, including reducing the company's carbon footprint and incorporating environmentally friendly packaging into its products. He also led the company's efforts to build a more integrated and innovative supply chain through the acquisition of several manufacturing companies.

    "We are grateful to Ritch for his tremendous leadership and all he has done to help position Nu Skin for further growth and success in the years to come," said Steven J. Lund, executive chairman of the board. "Ritch has exemplified our mission and vision every day for more than 30 years and is a force for good in every way. We are equally confident in Ryan and his ability to continue to lead Nu Skin to a bright and successful future. Together, Ritch and Ryan have built a strategy and vision that I believe will successfully drive Nu Skin forward for years to come."

    "It has truly been my honor to be the CEO of Nu Skin and lead an amazing team focused on improving people's lives all around the world. I have such admiration for our global Nu Skin family, including our talented sales leaders and dedicated employees," said Wood. "The time is right for Ryan to take the reins, consistent with our succession planning process when we stepped into our roles together four years ago. Ryan has played a critical leadership role in developing and executing our strategy and evolving Nu Skin into a more customer-obsessed, global, digital-first organization. He exemplifies Nu Skin's mission and is absolutely the right person to lead the company to even greater heights."

    Napierski, who has been with Nu Skin for 25 years, has served as Nu Skin's president for the past four years. Prior to that, he served as president of global sales and operations and lived abroad while serving as president of Nu Skin Japan and of Nu Skin's North Asia region and leading and executing Nu Skin's strategy in EMEA. Napierski has a bachelor's degree in business, an MBA from Duke University and a master's degree in international business from Goethe Universitat in Germany.

    Napierski added, "I am honored to be given the opportunity to serve as Nu Skin's next CEO and appreciate the confidence of the Board and Ritch. Nu Skin is family to me, and I am fortunate to work alongside an incredible, global team of employees and sales leaders to fulfill our mission of empowering people to improve lives."

    About Nu Skin Enterprises, Inc.
    Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies and life-improving values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskinenterprises.com.

    Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements of future Board and management members; statements of management's expectations regarding the company's growth, initiatives and future performance; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "will," "anticipate," "confident," "future," "believe," "expect," and other similar words. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from the forward-looking statements expressed herein. These risks and uncertainties include, but are not limited to, competitive pressures for personnel, economic and competitive conditions in our business and the markets in which we operate, potential failure of current or planned initiatives or products to generate and sustain interest among our sales force and customers, and regulatory risks associated with our products and business models. The forward-looking statements are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's expectations and beliefs as of the date that such information was first provided, and the company assumes no duty to update them to reflect any change except as required by law.

    SOURCE Nu Skin Enterprises

    Related Links

    http://nuskinenterprises.com

    Get the next $NUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Campbell Daniel W was granted 18,008 shares, increasing direct ownership by 60% to 48,262 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:50:59 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Nathanson Laura was granted 18,008 shares, increasing direct ownership by 83% to 39,638 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:49:32 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Thomas Pisano R. was granted 18,008 shares, increasing direct ownership by 25% to 90,184 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:45:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      5/28/25 6:26:44 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nu Skin Enterprises Appoints James Winett to Board of Directors

      Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

      6/2/25 12:19:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Financials

    Live finance-specific insights

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/12/24 4:47:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/6/24 10:20:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/4/24 10:21:31 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    SEC Filings

    See more
    • SEC Form S-8 filed by Nu Skin Enterprises Inc.

      S-8 - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      6/2/25 4:25:09 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/30/25 4:05:53 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SD filed by Nu Skin Enterprises Inc.

      SD - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/27/25 6:01:26 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nu Skin downgraded by Jefferies with a new price target

      Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

      1/31/23 6:17:27 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

      DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

      2/17/22 4:46:52 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

      Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

      11/24/21 11:03:39 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nu Skin Enterprises Appoints James Winett to Board of Directors

      Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

      6/2/25 12:19:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

      Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

      9/12/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care